Geertruida L. E. Romeijn

Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

Joanne R Chalmers, Kim S Thomas, Christian Apfelbacher et al. · British Journal of Dermatology · 2018 · 160 citations · Full text

Medicine, Dermatology, Pediatrics +15

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

Lieneke F.M. Ariëns, Jorien van der Schaft, Lotte S. Spekhorst et al. · Journal of the American Academy of Dermatology · 2020 · 91 citations · Full text

Life Sciences, Dermatology, Immunology +12

Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study

Jart A. F. Oosterhaven, Angelique N. Voorberg, Geertruida L. E. Romeijn et al. · The Journal of Dermatology · 2019 · 69 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15

Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

Lotte S. Spekhorst, Daphne S. Bakker, Julia Drylewicz et al. · Allergy · 2022 · 56 citations · Full text

Medicine, Dermatology, Pharmacology +13

The long‐term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis—52 week results from the Dutch <scp>BioDay</scp> Registry

Angelique N. Voorberg, Geertruida L. E. Romeijn, Marjolein de Bruin‐Weller et al. · Contact Dermatitis · 2022 · 45 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16